Analgesic strategies aimed at stimulating the endogenous production of allopregnanolone

• Published in: Frontiers in cellular neuroscience Vol. 8; p. 174
• Main Authors: Poisbeau, Pierrick, Keller, Anne Florence, Aouad, Maya, Kamoun, Nisrine, Groyer, Ghislaine, Schumacher, Michael
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Research Foundation 17-06-2014; Frontiers Media S.A
• Subjects: allodynia; Allosteric properties; Amnesia; Analgesics; Anesthetics; Binding sites; Cholesterol; Enzymes; etifoxine; Females; Hormones; Hyperalgesia; Kinases; Metabolites; Nervous system; Neuromodulation; Neuroscience; Neurosteroids; Nociception; Pain; Pregnanolone; Progesterone; Proteins; Rodents; Side effects; Spinal cord; Steroid hormones; Steroids; Testosterone; γ-Aminobutyric acid A receptors; France; nociception; allodynia; etifoxine; pain; hyperalgesia; neurosteroids
• ISSN: 1662-5102; 1662-5102
• DOI: 10.3389/fncel.2014.00174

A growing number of studies indicate that 3-alpha reduced neurosteroids are remarkable analgesics in various pain states. This is the case for allopregnanolone (AP), one of the most potent endogenous positive allosteric modulators of GABAA receptor function. From the pioneering work of Hans Selye, who described the sedative properties of steroids, synthetic compounds resembling the progesterone metabolite AP have been developed. If some of them have been used as anesthetics, it seems difficult to propose them as a therapeutic option for pain since they display several adverse side effects such as sedation, amnesia and functional tolerance. An alternative strategy, chosen by few laboratories around the world, is aimed at stimulating the local production of 3-alpha reduced neurosteroids in order to limit these well-known side effects. This pharmacological approach has the advantage of targeting specific structures, fully equipped with the necessary biosynthetic enzymatic machinery, where neurosteroids already act as endogenous pain modulators. The various pharmacological trials which attempted to treat pain symptoms by stimulating the production of 3-alpha reduced neurosteroids are reviewed here, as well as novel neurotransmitter systems possibly regulating their endogenous production.